Entering text into the input field will update the search result below

Johnson & Johnson cuts 2022 guidance as MedTech underperforms in 2Q

Jul. 19, 2022 7:00 AM ETJohnson & Johnson (JNJ)By: Dulan Lokuwithana, SA News Editor21 Comments

Johnson & Johnson offices in Silicon Valley

Sundry Photography/iStock Editorial via Getty Images

Despite reporting better-than-expected financials for 2Q 2022, Johnson & Johnson (NYSE:JNJ) slashed its full-year guidance Tuesday while the company’s MedTech segment contracted during the quarter.

Revenue for the quarter rose ~3% YoY to $24.0B as the pharma

Recommended For You

Comments (21)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

When nominal dollar earnings are declining in a high inflammation environment does it mean that nominal dollar earnings need to increase by the amount of inflation to be where they were last year?.
From the third to last paragraph above, guidance was "slashed". Consensus was $10.27; now guidance is $10.05 at the midpoint. Methinks the SA writers are being a bit overdramatic.
Not what cfo just said.
This is why sa is getting its rep.
Edward J. Roche profile picture
Compare this mediocre performance with that of UNH which also recently reported. JNJ lowering guidance, UNH raising guidance. UNH is the best healthcare large company stock.
@, good quarter again.
@Edward J. Roche
Of course, UNH is US, JNJ is international. It’s the dollar.
“slashed” . Current estimate for eps is 10.19 .
@Buyside Guy, CFA “If it bleeds, it leads”. Irresponsible comment by SA.
Willow Street Investments profile picture
@Buyside Guy, CFA Agreed. Financial reporting leaves less to be desired. Overly dramatic.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.